SCHEDULE: Lynwood Capital Management Reports Stake in Rein Therapeutics

Lynwood Capital Management Inc., Ben Shapiro, and Lynwood Opportunities Master Fund have reported beneficial ownership of 5.0% of Rein Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Lynwood Capital Management Inc., Ben Shapiro, and Lynwood Opportunities Master Fund (collectively, the Reporting Persons) have filed a Schedule 13G, indicating their beneficial ownership of Rein Therapeutics, Inc. common stock.
• As of June 30, 2026, the Reporting Persons collectively beneficially owned 4,280,500 shares of Rein Therapeutics' common stock.
• This ownership stake represents 5.0% of the class of securities outstanding.
• The filing specifies that Lynwood Opportunities Master Fund directly owns the shares, with Lynwood Capital Management Inc. acting as the investment manager, and Ben Shapiro as the controlling stockholder and officer of the investment manager.
• Each reporting person disclaims beneficial ownership of shares not directly owned by them.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• The filing clearly delineates the beneficial ownership structure, providing transparency regarding a significant shareholder.
• The Reporting Persons certify that the securities were not acquired for the purpose of influencing control of the issuer.

Negatives

• No new financial performance data or strategic initiatives are disclosed in this filing.

Risks

• Potential for future changes in beneficial ownership that could impact the company's stock price or control structure.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future performance.

Management Comments

• Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds, indicating a passive investment approach rather than an attempt to gain control. This filing provides transparency on a significant passive stake in Rein Therapeutics.

Stakeholder Impact

• Shareholders gain clarity on a significant beneficial owner, potentially influencing market perception and trading activity.

Next Steps

• The Reporting Persons will continue to monitor their investment in Rein Therapeutics, Inc.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Rein Therapeutics, Lynwood Capital Management, Investment Manager, Master Fund, Securities Ownership